Bionuclex is chasing one of the harder problems in biotech: catching multiple cancers early, from a single blood draw, in a way the average person could actually access.

Their focus is biomarker discovery for multi-cancer early detection liquid biopsy, the kind of work that only pays off if the science holds up under real scrutiny, and reaches further than a lab.